XNCR
What one share of Xencor holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. We use our protein engineering capabilities to design new technologies and XmAb® drug candidates with improved properties and multi-target mechanisms of action.
Xencor’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.40 |
|---|---|
| Profit | −$2.18 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$2.78 |
| Cash and investments | $0.60 |
| Debt | $1.04 |
| Book value | $6.77 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.57 | $1.06 | $0.04 | $2.21 | — | $7.26 |
| 2017 | $0.99 | −$0.82 | $0.11 | −$0.83 | — | $6.73 |
| 2018 | $0.75 | −$1.31 | $0.13 | −$1.61 | — | $9.27 |
| 2019 | $2.68 | $0.46 | $0.13 | $0.98 | — | $10.42 |
| 2020 | $2.14 | −$1.21 | $0.18 | −$0.27 | — | $9.89 |
| 2021 | $4.55 | $1.37 | $0.22 | −$0.50 | — | $12.36 |
| 2022 | $2.76 | −$0.93 | $0.65 | −$0.23 | — | $12.13 |
| 2023 | $2.89 | −$2.20 | $0.30 | −$1.59 | — | $10.85 |
| 2024 | $1.70 | −$3.58 | $0.09 | −$3.20 | — | $9.64 |
| 2025 | $1.69 | −$1.24 | $0.04 | −$1.86 | — | $8.84 |